General description

A cell-permeable imidazoquinazoline compound that acts as a potent, reversible, and ATP-competitive inhibitor against all three classes of PI 3-K kinases (IC₅₀ = 11, 18, 47, 58, 64, 350, and 830 nM against p110α, p110γ, PI 3-KC2α, p110δ, PI 3-KC2β, p110β, and hsVPS34, respectively), as well as several PIKKs (IC₅₀ = 13, 610, and 1050 nM against DNA-PK, ATM, and mTORC1, respectively) and PI 4-KIIIα (IC₅₀ = 830 nM), while exhibiting much reduced potency against PI 4-KIIIβ and ATR (IC₅₀ = 3.1 and 15 µM, respectively) and little or no activity toward PI 4-KIIα, PIPKs (IC₅₀ >100 µM), and a panel of 36 commonly studied protein kinases (﹤15% inhibition at 10 µM). Effectively suppreses insulin-stimulated phosphorylations of Akt and rpS6 in 3T3-L1 adipocytes and L6 myotubes in a dose-dependent manner in vitro (by >90% at 2.5 µM) and completely prevents insulin-induced blood glucose decline in mice in vivo (10 mg/ml, i.p.).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Fan, Q.W., et al. 2007. Cancer Res.67, 7960.Fan, Q.W., et al. 2006. Cancer Cell9, 341.Knight, Z.A., et al. 2006. Cell125, 733.

Packaging

Packaged under inert gas

5 mg in Plastic ampoule

Preparation Note

Slight warming may be required to for complete solubility.

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)